iRegene Therapeutics secures series B+ financing
NouvNeu001 is the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive this designation
NouvNeu001 is the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive this designation
Products manufactured at the new Vaughan facility will support research in areas including cancer, infectious disease, mental health, and environmental safety
Maria Soler Nunez appointed as Chief Quality Officer
The portfolio acquired includes Stugeron brand as well as its leading local brands STUGERON FORTE and STUGERON PLUS across 18 markets in the APAC and EMEA regions
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients
Sun Pharma's Halol plant gets OAI classification from US FDA inspection
Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
Subscribe To Our Newsletter & Stay Updated